Cargando…

HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions

Background: HPV tests differ for technology, targets, and information on genotyping of high risk (HR) HPV. In this study, we evaluated the performance of 6 HPV DNA tests and one mRNA test in the detection of cervical intraepithelial lesions (CIN) and as a test-of-cure in the follow-up after surgical...

Descripción completa

Detalles Bibliográficos
Autores principales: Bottari, Fabio, Iacobone, Anna Daniela, Radice, Davide, Preti, Eleonora Petra, Preti, Mario, Franchi, Dorella, Boveri, Sara, Sandri, Maria Teresa, Passerini, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600734/
https://www.ncbi.nlm.nih.gov/pubmed/36292048
http://dx.doi.org/10.3390/diagnostics12102359
_version_ 1784816916612775936
author Bottari, Fabio
Iacobone, Anna Daniela
Radice, Davide
Preti, Eleonora Petra
Preti, Mario
Franchi, Dorella
Boveri, Sara
Sandri, Maria Teresa
Passerini, Rita
author_facet Bottari, Fabio
Iacobone, Anna Daniela
Radice, Davide
Preti, Eleonora Petra
Preti, Mario
Franchi, Dorella
Boveri, Sara
Sandri, Maria Teresa
Passerini, Rita
author_sort Bottari, Fabio
collection PubMed
description Background: HPV tests differ for technology, targets, and information on genotyping of high risk (HR) HPV. In this study, we evaluated the performance of 6 HPV DNA tests and one mRNA test in the detection of cervical intraepithelial lesions (CIN) and as a test-of-cure in the follow-up after surgical conservative treatment. Methods: One hundred seventy-two women referred to the European Institute of Oncology, Milan, for surgical treatment of pre-neoplastic cervical lesions, were enrolled in this study (IEO S544) from January 2011 to June 2015. For all women, a cervical sample was taken before treatment (baseline) and at the first follow-up visit (range 3 to 9 months): on these samples Qiagen Hybrid Capture 2 (HC2), Roche Linear Array HPV Test (Linear Array), Roche Cobas 4800 HPV test (Cobas), Abbott RealTime High Risk HPV test (RT), BD Onclarity HPV assay (Onclarity), Seegene Anyplex II HPV HR Detection (Anyplex), and Hologic Aptima HPV Assay (Aptima) histology and cytology were performed at baseline, and the same tests and cytology were performed at follow-up. Results: At baseline 158/172 (92%), histologies were CIN2+, and 150/172 (87%) women were recruited at follow-up. Assuming HC2 as a comparator, the concordance of HPV tests ranges from 91% to 95% at baseline and from 76% to 100% at follow-up (PABAK ranging from 0.81 to 0.90 at baseline and PABAK ranging from 0.53 to 1 at follow-up). All HPV showed a very good sensitivity in CIN2+ detection at baseline, more than 92%, and a very good specificity at follow-up, more than 89%. Conclusions: HPV tests showed a good concordance with HC2 and a very good and comparable sensitivity in CIN2+ detection. Hence, an HPV test represents a valid option as test-of-cure in order to monitor patients treated for CIN2+ lesions during follow-up.
format Online
Article
Text
id pubmed-9600734
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96007342022-10-27 HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions Bottari, Fabio Iacobone, Anna Daniela Radice, Davide Preti, Eleonora Petra Preti, Mario Franchi, Dorella Boveri, Sara Sandri, Maria Teresa Passerini, Rita Diagnostics (Basel) Article Background: HPV tests differ for technology, targets, and information on genotyping of high risk (HR) HPV. In this study, we evaluated the performance of 6 HPV DNA tests and one mRNA test in the detection of cervical intraepithelial lesions (CIN) and as a test-of-cure in the follow-up after surgical conservative treatment. Methods: One hundred seventy-two women referred to the European Institute of Oncology, Milan, for surgical treatment of pre-neoplastic cervical lesions, were enrolled in this study (IEO S544) from January 2011 to June 2015. For all women, a cervical sample was taken before treatment (baseline) and at the first follow-up visit (range 3 to 9 months): on these samples Qiagen Hybrid Capture 2 (HC2), Roche Linear Array HPV Test (Linear Array), Roche Cobas 4800 HPV test (Cobas), Abbott RealTime High Risk HPV test (RT), BD Onclarity HPV assay (Onclarity), Seegene Anyplex II HPV HR Detection (Anyplex), and Hologic Aptima HPV Assay (Aptima) histology and cytology were performed at baseline, and the same tests and cytology were performed at follow-up. Results: At baseline 158/172 (92%), histologies were CIN2+, and 150/172 (87%) women were recruited at follow-up. Assuming HC2 as a comparator, the concordance of HPV tests ranges from 91% to 95% at baseline and from 76% to 100% at follow-up (PABAK ranging from 0.81 to 0.90 at baseline and PABAK ranging from 0.53 to 1 at follow-up). All HPV showed a very good sensitivity in CIN2+ detection at baseline, more than 92%, and a very good specificity at follow-up, more than 89%. Conclusions: HPV tests showed a good concordance with HC2 and a very good and comparable sensitivity in CIN2+ detection. Hence, an HPV test represents a valid option as test-of-cure in order to monitor patients treated for CIN2+ lesions during follow-up. MDPI 2022-09-29 /pmc/articles/PMC9600734/ /pubmed/36292048 http://dx.doi.org/10.3390/diagnostics12102359 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bottari, Fabio
Iacobone, Anna Daniela
Radice, Davide
Preti, Eleonora Petra
Preti, Mario
Franchi, Dorella
Boveri, Sara
Sandri, Maria Teresa
Passerini, Rita
HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions
title HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions
title_full HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions
title_fullStr HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions
title_full_unstemmed HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions
title_short HPV Tests Comparison in the Detection and Follow-Up after Surgical Treatment of CIN2+ Lesions
title_sort hpv tests comparison in the detection and follow-up after surgical treatment of cin2+ lesions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600734/
https://www.ncbi.nlm.nih.gov/pubmed/36292048
http://dx.doi.org/10.3390/diagnostics12102359
work_keys_str_mv AT bottarifabio hpvtestscomparisoninthedetectionandfollowupaftersurgicaltreatmentofcin2lesions
AT iacoboneannadaniela hpvtestscomparisoninthedetectionandfollowupaftersurgicaltreatmentofcin2lesions
AT radicedavide hpvtestscomparisoninthedetectionandfollowupaftersurgicaltreatmentofcin2lesions
AT pretieleonorapetra hpvtestscomparisoninthedetectionandfollowupaftersurgicaltreatmentofcin2lesions
AT pretimario hpvtestscomparisoninthedetectionandfollowupaftersurgicaltreatmentofcin2lesions
AT franchidorella hpvtestscomparisoninthedetectionandfollowupaftersurgicaltreatmentofcin2lesions
AT boverisara hpvtestscomparisoninthedetectionandfollowupaftersurgicaltreatmentofcin2lesions
AT sandrimariateresa hpvtestscomparisoninthedetectionandfollowupaftersurgicaltreatmentofcin2lesions
AT passerinirita hpvtestscomparisoninthedetectionandfollowupaftersurgicaltreatmentofcin2lesions